Luspatercept
Generic name: Luspatercept
Brand names: Reblozyl
Dosage form: subcutaneous powder for injection (aamt 25 mg; aamt 75 mg)
Drug class:
Miscellaneous erythropoiesis agents
Usage of Luspatercept
Luspatercept is for use in adults with a blood disorder called beta thalassemia, in which the body does not produce enough hemoglobin (HEEM o glo bin). Hemoglobin carries oxygen through your blood to tissues and organs.
Luspatercept is used to treat anemia (lack of red blood cells) in adults with beta thalassemia who need to have regular red blood cell transfusions.
Luspatercept may also be used for purposes not listed in this medication guide.
Luspatercept side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have:
Your luspatercept injections may be delayed or permanently discontinued if you have certain side effects.
Common side effects of luspatercept may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Luspatercept
Tell your doctor if you have ever had:
Tell your doctor if you are pregnant or could become pregnant. Luspatercept may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using luspatercept and for at least 3 months after your last dose.
Do not breastfeed while using this medicine, and for at least 3 months after your last dose.
Relate drugs
How to use Luspatercept
Usual Adult Dose for Anemia:
Initial dose: 1 mg/kg suBCutaneously once every 3 weeks-If no reduction in red blood cell transfusions after 2 doses (6 weeks), increase to 1.25 mg/kg.Maximum dose: 1.25 mg/kgComments:-This drug is not a substitute for red blood cell transfusions in the immediate correction of anemia.-Assess and review hemoglobin (Hgb) prior to each administration; if a red blood cell transfusion occurred prior to dosing, use pretransfusion Hgb for dosing purposes.-If pre-dose Hgb is 11.5 g/dL or higher (not related to recent transfusion), delay dose until Hgb is 11 g/dL or less.-If treatment response is lost, search for causative factors (e.g. bleeding event); if typical causes are excluded, increase dose to 1.25 mg.-Discontinue therapy if no decrease in transfusions is seen after 9 weeks (3 doses) at the maximum dose or unacceptable toxicity occurs (at any time).Use: Treatment of anemia in beta thalassemia patients who require regular red blood cell transfusions.
Usual Adult Dose for Thalassemia:
Initial dose: 1 mg/kg subcutaneously once every 3 weeks-If no reduction in red blood cell transfusions after 2 doses (6 weeks), increase to 1.25 mg/kg.Maximum dose: 1.25 mg/kgComments:-This drug is not a substitute for red blood cell transfusions in the immediate correction of anemia.-Assess and review hemoglobin (Hgb) prior to each administration; if a red blood cell transfusion occurred prior to dosing, use pretransfusion Hgb for dosing purposes.-If pre-dose Hgb is 11.5 g/dL or higher (not related to recent transfusion), delay dose until Hgb is 11 g/dL or less.-If treatment response is lost, search for causative factors (e.g. bleeding event); if typical causes are excluded, increase dose to 1.25 mg.-Discontinue therapy if no decrease in transfusions is seen after 9 weeks (3 doses) at the maximum dose or unacceptable toxicity occurs (at any time).Use: Treatment of anemia in beta thalassemia patients who require regular red blood cell transfusions.
Warnings
Before using luspatercept tell your doctor about all your medical conditions or allergies, all medicines you use, and if you are pregnant or breastfeeding.
What other drugs will affect Luspatercept
Other drugs may affect luspatercept, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions